Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
1. NEUP achieves target enrollment of 332 participants for AFFIRM-1 Phase 3 trial. 2. BNC-210 shows promise as a fast-acting treatment for social anxiety disorder. 3. Phase 3 data for BNC-210 expected early Q4 2025, essential for market positioning. 4. Social anxiety disorder affects 31 million Americans, indicating large potential market. 5. BNC-210 has received FDA Fast Track designation, enhancing development prospects.